Middle dose level: 1.0×10^6 UCAR+ T Cells/kg

2 trials

Sponsors

Zhongshan People's Hospital

Conditions

Advanced gastric cancerRelapsed/refractory CD19-positive B-cell malignancies

Early Phase 1

To evaluate the safety and tolerability of CLDN18.2 UCAR-T cell injection in advanced gastric cancer with metastasis and recurrence after total gastrectomy

RecruitingChiCTR2000039851

Zhongshan People's HospitalAdvanced gastric cancer

Start: 2021-01-01Updated: 2021-02-22

To evaluate the safety and tolerability of CD19 UCAR-T cell injection in subjects with recurrent/refractory CD19 positive B cell malignancies

RecruitingChiCTR2000039849

Zhongshan People's HospitalRelapsed/refractory CD19-positive B-cell malignancies

Start: 2021-01-01Updated: 2021-02-22